Fluvoxamine and Ivermectin: Early treatment for COVID-19 is key to better outcomes (May 2022)
FluvoxamineOne of them, the generic drug fluvoxamine, has shown huge potential. Developed 40 years ago as an antidepressant, fluvoxamine—sometimes known as Luvox (brand name) - has been used mainly to treat obsessive-compulsive disorder (OCD), per the National Alliance on Mental Illness (NAMI). But now, researchers are taking a closer look at how the medication could be an important treatment to prevent patients who test positive for COVID-19 from getting seriously ill with the infection.
In December 2021, Dr. David R Boulware requested an emergency use authorization for the outpatient treatment of adults testing positive for SARS-CoV-2 to prevent progression to severe symptoms based on early efficacy data from the fluvoxamine trials. The Food and Drug Administration denied his request, listing concerns such as insufficient data.
The FDA found that the success of the trial was fueled by the six-hour threshold, which they found to be arbitrary. A patient remaining in the emergency room for 5.9 hours after taking fluvoxamine was considered a positive data point, whereas 6.1 hours was considered a negative. In the FDA’s words, “there are uncertainties about…whether the 6-hour timepoint represents a clinically meaningful threshold.”
The other three trials were found to be inconclusive as well. The FDA noted that the STOP COVID trial had several damaging design flaws, including a lack of randomization, a small sample size, and only a single testing center. The STOP COVID 2 trial and the COVID-OUT trial both failed to demonstrate a positive efficacy for fluvoxamine and were terminated early for futility.
Fluvoxamine and COVID-19 Early Treatment Fund
Ivermectin is an anti-parasitic medication widely used in low- and middle-income countries to treat parasitic worm infections in adults and children. It’s been used for decades for this purpose by over 3.7 billion people, and is considered safe and effective. It has an increasing list of indications due to its antiviral and anti-inflammatory properties, and is included on the WHO’s Model List of Essential Medicines.
Fluvoxamine, Ivermectin and FLCCC I-MASK+ Protocol
Note about TOGETHER trial results for fluvoxamine and ivermectin
We don't think the trial was gamed at all. I think this was a legit result.
We know the Principal Investigator Edward Mills and believe he is totally honest and we have no reason not to believe the results he obtained. But we also believe other researchers as well.
So the question everyone has is how could these drugs do so well in other studies?
The answer: the variant was different. P1 is the variant in Brazil and makes Delta look like a walk in the park. If you do not treat P1, instantly upon symptoms, you will see big failures.
Had fluvoxamine been given on Day 0 instead of Day 4, there would have been a dramatically different result.
Had ivermectin been dosed at 0.6mg/day for 14 days starting on Day 0 (the first day of symptoms), there would have been a dramatically different result.
The more aggressive the variant, the earlier and harder you have to treat it.
Ivermectin likely failed for these four reasons:
- too little a dose
- started too late
- not continued for long enough
- many patients may have already been taking ivermectin
Also, you can't treat Delta and P1 in the hospital... it is much much tougher there. It's like a fire department arriving when the entire building is in flames.
Fluvoxamine vs Other OptionsThe recommendations below are based on both scientific studies and the experience of clinicians in treating COVID-19.
Find a Doctor who will Prescribe Fluvoxamine in US
13690 E 14th St., Suite 100, San Leandro, CA 94578
1300 Clay St St., Suite 165, Oakland, CA 94612